Use of cDNA-Expressed Human Cytochrome P450 Enzymes to Study Potential Drug-Drug Interactions

Advances in Pharmacology

Volumn 43, Issue C, 1997, Pages 171-188

  Crespi, Charles L ^a   Penman, Bruce W ^a  

^a Gentest Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYP2C9 PROTEIN, HUMAN; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; CYTOCHROME P450 2D6; DRUG; MIXED FUNCTION OXIDASE; STEROID 16ALPHA MONOOXYGENASE; STEROID MONOOXYGENASE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; DRUG ANTAGONISM; DRUG INTERACTION; DRUG SCREENING; HUMAN; LIVER; METABOLISM; MICROSOME;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HUMANS; LIVER; MICROSOMES; MIXED FUNCTION OXYGENASES; PHARMACEUTICAL PREPARATIONS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TUMOR CELLS, CULTURED;

EID: 0030627339     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60205-7     Document Type: Article

References (44)

1. Buters J.T.M., Korzekwa K.R., Kunze K.L., Omata Y., Hardwick J.P., and Gonzalez F.J. cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab. Dispos. 22 (1994) 688-692
2. Code E.L., Crespi C.L., Penman B.W., Gonzalez F.J., Chang T.K.H., and Waxman D.J. Human cytochrome P450286: Interindividual hepatic expression, substrate specificity and role in procarcinogen activation. Drug Metab. Disp. (1997) (in press)
3. Crespi C.L. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv. Drug Res. 26 (1995) 179-235
4. Crespi C.L., Penman B.W., Leakey J.A.E., Arlotto M.P., Stark A., Turner T., Steimel D., Rudo K., Davies R.L., and Langenbach R.L. Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis (London) 8 (1990) 1293-1300
5. Crespi C.L., Gonzalez F.J., Steimel D.T., Turner T.R., Gelboin H.V., Penman B.W., and Langenbach R. A metabolically competent cell line expressing five cDNAs encoding procarcinogen-activating enzymes: Applications to mutagenicity testing. Chem. Res. Toxicol. 4 (1991) 566-572
6. Crespi C.L., Penman B.W., Steimel D.T., Gelboin H.V., and Gonzalez F.J. The development of a human cell line stably expressing human CYP3A4: Role in the metabolic activation of aflatoxin B1 and comparison to CYP1A2 and CYP2A3. Carcinogenesis (London) 12 (1991) 355-359
7. Crespi C.L., Gonzalez F.J., Steimel D.T., Turner T.R., Gelboin H.V., Penman B.W., and Langenbach R. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone, is activated by multiple human cytochrome P450S including the polymorphic cytochrome P4502D6. Carcinogenesis (London) 12 (1991) 1197-1201
8. Crespi C.L., Langenbach R., and Penman B.W. Human cell lines, derived from AHH-1 TK± human lymphoblasts, genetically engineered for expression of cytochromes P450. Toxicology 82 (1993) 89-104
9. Crespi C.L., Steimel D.T., Penman B.W., Korzekwa K.R., Fernandez-Salguero P., Buters J.T.M., Gelboin H.V., Gonzalez F.J., Idle J.R., and Daly A.K. Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. Pharmacogenetics 5 (1995) 234-243
10. Dayer P., Kronbach T., Eichelbaum M., and Mayer U.A. Enzymatic basis of the debrisoquine/sparteine-type polymorphism of drug oxidation. Biochem. Pharmacol. 36 (1987) 4145-4152
11. Doehmer J., Dogra S., Friedberg T., Monier S., Adesnik M., Glatt H., and Oesch F. Stable expression of rat cytochrome P450IIB1 cDNA in Chinese hamster cells (V79) and metabolic activation of aflatoxin B1. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 5769-5773
12. First M.R., Schroeder T.J., Alexander J.W., Stephens G.W., Weiskittel P., Myre S.A., and Pesci A.J. Cyclosporine dose reduction by ketoconazole administration in renal transplant patients. Transplantation 51 (1991) 365-370
13. Furuya H., Fernandez-Salguero P., Gregory W., Taber H., Steward A., Gonzalez F.J., and Idle J.R. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5 (1995) 389-392
14. Gillam E.M.J., Baba T., Kim B.-R., Ohmori S., and Guengerich F.P. Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys. 305 (1993) 123-131
15. Gonzalez F.J. The molecular biology of cytochrome P450s. Pharmacol. Rev. 40 (1989) 243-288
16. Gonzalez F.J., and Gelboin H.V. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab. Rev. 26 (1994) 165-183
17. Gonzalez F.J., and Korzekwa K.R. Cytochromes P450 expression systems. Annu. Rev. Pharmacol. Toxicol. 35 (1995) 369-390
18. Guengerich F.P., Muller-Enoch D., and Blair I.A. Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol. 30 (1986) 287-295
19. Kronbach T., Mathys D., Gut J., Catin T., and Meyer U.A. High performance liquid chromatographic assays for bufuralol 1′hydroxylation, debrisoquine 4-hydroxylation and dextromethorphan O-demethylation in microsomes and purified cytochrome P-450 isozymes of human liver. Anal. Biochem. 162 (1987) 24-32
20. Leeman T., Transon C., and Dayer P. Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxyation in human liver. Life Sci. 52 (1993) 29-34
21. Mahgoub A., Idle J.R., Dring L.G., Lancaster R., and Smith R.L. Polymorphic oxidation of debrisoquine in man. Lancet 2 (1977) 584-586
22. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gotoh O., Coon M.J., Estabrook R.W., Gunsalus I.C., and Nebert D.W. P450 superfamily:update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6 (1996) 1-42
23. Omura T., and Sato R. The carbon monoxide-binding pigment of liver microsomes II: Solubilization, purification and properties. J. Biol. Chem. 239 (1964) 2379-2385
24. Penman B.W., and Crespi C.L. Analysis of human lymphoblast mutation assays by using historical negative control data bases. Envron. Mol. Mutagen. 10 (1987) 35-60
25. Penman B.W., Reece J., Smith T., Yang C.S., Gelboin H.V., Gonzales F.J., and Crespi C.L. Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics 3 (1993) 28-39
26. Penman B.W., Chen L.P., Gelboin H.V., Gonzalez F.J., and Crespi C.L. Development of a human lymphoblastoid cell line constitutively expressing human CYP1A1 cDNA-substrate specificity with model substrates and promutagens. Carcinogenesis (London) 15 (1994) 1931-1937
27. Peyronneau M.-A., Renaud J.-P., Truan G., Urban P., Pompon D., and Mansuy D. Optimization of yeast-expressed human liver cytochrome P450 3A4 catalytic activities by co-expressing NADPH-cytochrome P450 reductase and cytochrome b5. Eur. J. Biochem. 207 (1992) 109-116
28. Phillips A.H., and Langdon R.G. Hepatic triphosphopyridine nucleotide cytochrome C reductase: Isolation, characterization and kinetic studies. J. Biol. Chem. 237 (1962) 2652-2660
29. Rettie A.E., Wienkers L.C., Gonzales F.J., Trager W.F., and Korzekwa K.R. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4 (1994) 39-42
30. Romkes M., Feletto M.B., Baisdell J.A., Raucy J.L., and Goldstein J.A. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 30 (1991) 3247-3255
31. Schenkman J.B., Voznesensky A.I., and Jansson I. Influence of inonic strength on the P450 monooxygeanse reaction and the role of cytochrome b5 in the process. Arch. Biochem. Biophys. 314 (1994) 234-241
32. Shimada T., Misono K.S., and Guengerich F.P. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative metabolism. J. Biol. Chem. 261 (1986) 909-921
33. Shimada T., Yamazaki H., Mimura M., Inui Y., and Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals-studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270 (1994) 414-423
34. Song B.-J., Gelboin H.V., Park S.-S., Yang C.S., and Gonzalez F.J. Complementary DNA and protein sequences of ethanol-inducible rat and human cytochrome P-450's. J. Biol. Chem. 261 (1996) 16689-16697
35. Spatzenegger M., and Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab. Rev. 27 (1995) 397-417
36. Sugden B., Marsh K., and Yates J. A vector that replicates as a plasmid and can be efficicently selected in B-lymphoblasts transformed by Epstein-Barr virus. Mol. Cell. Biol. 5 (1985) 410-413
37. Waterman M.R. Heterologous expression of cytochrome-P-450 i. Escherichia coli. Biochem. Soc. Trans. 21 (1993) 1081-1085
38. Watkins P.B., Wrighton S.A., Scheutz E.G., Molowa D.T., and Guzelian P.S. Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80 (1987) 1029-1036
39. Waxman D.J., Ko A., and Walsh C. Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. J. Biol. Chem. 258 (1983) 11937-11947
40. Waxman D.J., Attisano C., Guengerich F.P., and Lapenson D. Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys. 263 (1988) 424-436
41. Waxman D.J., Lapenson D.P., Aoyama T., Gelboin H.V., and Gonzalez F.J. Steroid hormone hydroxylase specifies of eleven cDNA-expressed human cytochrome P450 enzymes. Arch. Biochem. Biophys. 290 (1991) 160-166
42. Wrighton S.A., Steven J.C., Becker G.W., and VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylase. Arch. Biochem. Biophys. 306 (1993) 240-245
43. Yamazaki H., Guo Z.Y., Persmark M., Mimura M., Inoue K., Guengerich F.P., and Shimada T. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol. Pharmacol. 46 (1994) 568-577
44. Yates J.L., Warren N., and Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature (London) 313 (1985) 812-815